Vaishali Pharma Ltd. (IN:VAISHALI)
:VAISHALI
Top Page
Vaishali Pharma Ltd.
(VAISHALI)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹6.00
▼(-25.37% Downside)
Action:ReiteratedDate:04/02/26
The score is held back primarily by weak cash flow and deteriorating profitability, alongside strongly bearish technical signals (below key moving averages with negative MACD). These are partially offset by a relatively stable balance sheet and a mid-range valuation (P/E 21.332).
Positive Factors
Strong Revenue Growth
Sustained ~15% revenue growth indicates durable demand for the company’s products and expanding market penetration. Over a 2–6 month horizon this growth supports scale benefits, improves fixed-cost absorption, and provides a foundation to restore margins if cost headwinds are managed.
Negative Factors
Negative Operating Cash Flow
Material negative operating and free cash flow erode internal funding ability, forcing reliance on external financing or equity to fund capex and working capital. Over months this weakens financial flexibility, raises liquidity risk, and constrains capacity for R&D or commercial expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained ~15% revenue growth indicates durable demand for the company’s products and expanding market penetration. Over a 2–6 month horizon this growth supports scale benefits, improves fixed-cost absorption, and provides a foundation to restore margins if cost headwinds are managed.
Read all positive factors
Vaishali Pharma Ltd. (VAISHALI) vs. iShares MSCI India ETF (INDA)
Market Cap
₹637.79M
Dividend YieldN/A
Average Volume (3M)399.32K
Price to Earnings (P/E)21.3
Beta (1Y)1.23
Revenue Growth18.35%
EPS Growth-154.65%
CountryIN
Employees27
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.10
Shares Outstanding107,192,130
10 Day Avg. Volume443,817
30 Day Avg. Volume399,324
Financial Highlights & Ratios
PEG Ratio-11.89
Price to Book (P/B)0.26
Price to Sales (P/S)0.17
P/FCF Ratio-0.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaishali Pharma Ltd. Business Overview & Revenue Model
Company Description
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, a...
How the Company Makes Money
null...
Vaishali Pharma Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
72
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.17B | 990.26M | 862.80M | 696.63M | 758.21M | 537.74M |
| Gross Profit | 115.79M | 102.85M | 96.43M | 129.19M | 80.36M | 61.56M |
| EBITDA | 9.74M | 32.95M | 31.71M | 113.59M | 86.44M | 44.42M |
| Net Income | -3.84M | 8.17M | 7.19M | 66.03M | 40.24M | 10.46M |
Balance Sheet | ||||||
| Total Assets | 1.22B | 1.10B | 799.56M | 789.07M | 816.24M | 861.23M |
| Cash, Cash Equivalents and Short-Term Investments | 10.46M | 18.43M | 14.57M | 124.24M | 11.62M | 3.13M |
| Total Debt | 156.01M | 125.53M | 134.92M | 147.36M | 208.11M | 178.50M |
| Total Liabilities | 545.40M | 449.29M | 371.16M | 383.76M | 552.70M | 637.05M |
| Stockholders Equity | 673.82M | 649.16M | 428.39M | 405.31M | 263.54M | 224.19M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -197.36M | 2.71M | 7.83M | 4.54M | 18.85M |
| Operating Cash Flow | 0.00 | -194.31M | 8.07M | 10.80M | 13.19M | 20.11M |
| Investing Cash Flow | 0.00 | -1.88M | 12.03M | 2.82M | -8.47M | -1.10M |
| Financing Cash Flow | 0.00 | 184.91M | -14.16M | -17.32M | 4.17M | -18.12M |
Vaishali Pharma Ltd. Technical Analysis
Neutral
8.04
Price Trends
7.03
Negative
7.94
Negative
9.86
Negative
Market Momentum
-0.34
Negative
47.72
Neutral
80.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VAISHALI, the sentiment is Neutral. The current price of 8.04 is above the 20-day moving average (MA) of 5.97, above the 50-day MA of 7.03, and below the 200-day MA of 9.86, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 47.72 is Neutral, neither overbought nor oversold. The STOCH value of 80.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:VAISHALI.
Vaishali Pharma Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ₹2.59B | 48.53 | ― | ― | -0.77% | 2055.99% | |
58 Neutral | ₹1.14B | 16.40 | ― | 1.62% | -9.07% | 5.36% | |
56 Neutral | ₹527.11M | 172.45 | ― | ― | 36.76% | 433.63% | |
52 Neutral | ₹637.79M | 21.33 | ― | ― | 18.35% | -154.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹1.69B | 84.53 | ― | ― | -17.47% | -50.07% | |
45 Neutral | ₹1.33B | -11.90 | ― | ― | -46.31% | -26.28% |
* Healthcare Sector Average
IN:VAISHALI
Vaishali Pharma Ltd.
5.95
-6.31
-51.47%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
59.60
11.59
24.14%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
109.60
36.60
50.14%
IN:BALPHARMA
Bal Pharma Limited
71.60
-31.48
-30.54%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
32.39
-11.39
-26.02%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
61.55
-9.74
-13.66%
Vaishali Pharma Ltd. Corporate Events
Vaishali Pharma Clarifies Preferential Issue Pricing in NSE-Directed Postal Ballot Corrigendum
Feb 28, 2026
Vaishali Pharma Ltd. has issued a corrigendum to its postal ballot notice following directions from the National Stock Exchange, providing additional details and amendments under SEBI’s capital and disclosure rules. The update clarifies the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.